Deutsche Bank raised the firm’s price target on Genmab (GMAB) to DKK 2,400 from DKK 2,000 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab price target raised to DKK 2,500 from DKK 2,000 at Barclays
- Genmab: Late-Stage Oncology Pipeline Catalysts Underpin Buy Rating and Upside Potential
- Genmab discontinuing acasunlimab a ‘good decision,’ says Guggenheim
- Genmab Drops Acasunlimab to Refocus Investment on Late-Stage Cancer Pipeline
- Genmab to discontinue clinical development of acasunlimab